ClinicalTrials.gg
RecruitingNCT06748937ENABLEUpdated Mar 7, 2025

A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

A Phase 2 interventional study of Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD and Alpibectir 45 mg OD plus Ethionamide 250 mg OD in Tuberculosis, sponsored by TASK Applied Science. Recruiting at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-07.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's title name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by TASK Applied Science · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Planned enrollment
58th of 67
60 · median 122
Started
2025
with 3 others
Phase 2
49 of 78
8 open now
Primary completion
2026-03
later than 3 of 12 live
Registered
72nd of 78
by date
Lead sponsor
6 of 78
TASK Applied Science

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 58th largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 49 in phase 2, reaches primary completion later than 3 of the 12 other live ones, and was the 72nd registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14.

15 participants will be recruited into each treatment arm in two sequential cohorts. Each cohort will have participants enrolled onto the experimental regimen(s) or the standard of care (SOC; HRZE) control arm.

  • Cohort 1 aims to generate safety data for a higher dose of alpibectir plus ethionamide 125 mg and 250 mg (arm 1: A45E125 and arm2: A45E250).

Once 5 participants have enrolled into arms 1 and 2 each, and completed 14 days of treatment, an interim safety review will be conducted to determine whether the study can advance to cohort 2.

  • Cohort 2 will investigate safety of alpibectir and ethionamide (A45E250) in combination with rifampicin, pyrazinamide and ethambutol (A45E250RZE).

Participants on HRZE will serve as control for the EBA quantitative mycobacteriology in each cohort, and additionally as a safety benchmark for the A45E250RZE arm. The study is not statistically powered to make between arm comparisons of activity or safety. The treatment will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.

Read the detailed description

This trial is designed to evaluate the antimycobacterial ejects and the safety of alpibectir in combination with other antimycobacterial agents, particularly Eto, over a 14-day period. The overarching objective is to optimise the dose of both alpibectir and ethionamide and to confirm the safety of the A45E250RZE regimen for future evaluation as an alternative regimen for INH mono-resistant TB. The data from the TASK-010 phase 2A and the ENABLE study will support evaluation of the optimal dose combination of AlpE to move forward into later phase studies. EBAs have historically been conducted between 2 and 14 days. This study will be a standard 14-day EBA design with multiple parallel and sequential treatment arms.

Cohort 1:

Arm 1 and 2: This cohort will add to the evidence base generated in the TASK-010 study (NCT05473195) to support dose optimisation of alpibectir and ethionamide (AlpE) and establish the safety of alpibectir 45 mg in humans, a dose which to date has not been evaluated.

Interim safety review: once a safety review of a subset of participants in arms 1 and 2 receiving the 45 mg dose of alpibectir is complete, cohort 2 will be permitted to begin recruiting once cohort 1 is complete.

Cohort 2:

Arm 4: will combine AlpE at doses determined to be safe and well tolerated from arms 1 and 2, with standard doses of rifampicin, isoniazid and ethambutol (A45E250RZE). Here AlpE replaces isoniazid in the regimen as part of the planned future use of the combination. This will establish the safety of this 5-drug combination at standard rifampicin doses. A well tolerated, adorable, oral, once daily dosing regimen would make the AlpE combination tolerable for patients and hence for the majority of people suffering from TB in less affluent regions of the world. All participants will remain under medical attention, and will be housed, and monitored in hospital from admission through day 15 of the treatment period; this will allow for continuous monitoring of the health status of each participant while initiating treatment, any of whom can be withdrawn at any stage of the trial and removed from study treatment should his/her condition suggest to the investigator that this would be in his/her best interest.

Biomarkers The traditional 2A proof-of-concept studies for new TB drugs also allow the exploration of new ways of measuring TB treatment activity in short-course trials beyond measurement of CFU or TTP. Each chemotherapeutic agent has the potential to contribute an interactive, often synergistic, role with other agents in a combination regimen, but this attribute is not captured by measuring decline in sputum CFU or TTP alone. Novel sputum biomarkers, and biomarkers from blood samples may have the potential to substitute or complement traditional sputum culture based methods to assess treatment responses. Host derived markers may also be able to describe the EBA of novel drugs.

Whole blood biomarkers:

Whole blood RNA analysis is emerging as a promising tool for the pathogen-free diagnosis and monitoring of TB treatment. This approach has the potential to revolutionize TB management by oqering a precise, individualized method to determine the duration of anti-TB therapy needed to achieve a relapse-free cure. The identification and validation of a 22-gene transcriptomic signature model (TB22) by Heyckendorf and colleagues serve as a significant advancement in this field. TB22 has shown superior performance in predicting individual treatment endpoints compared to 17 other publicly available RNA signatures. Specifically, TB22 demonstrated high accuracy in identifying end-of-therapy time points, with an AUC of 0.94 for predicting clinical outcomes. The model also indicated that cure could be achieved with significantly shorter treatment durations for patients with multidrug-resistant TB (MDR-TB). Whole blood will be collected in participants who consent for evaluation of whole blood RNA in models like the TB22 or others investigating the use of novel biomarkers.

Sputum biomarkers:

The Molecular Bacterial Load Assay (TB-MBLA) and PATHFAST (LAM) are novel biomarkers being evaluated for their potential to improve TB treatment monitoring. The TB-MBLA oqers a rapid and precise measurement of bacterial load by detecting RNA, which is less aqected by the presence of non-culturable bacteria. This assay, coupled with appropriate RNA preservatives, can provide real-time insights into the bacterial burden and treatment eqicacy. PATHFAST (LAM) focuses on detecting lipoarabinomannan (LAM) in sputum, a component of the mycobacterial cell wall. LAM detection can serve as a biomarker for active TB, providing an additional layer of diagnostic information. Its integration into treatment monitoring can help assess the eqicacy of TB drugs, particularly in reducing bacterial load in the lungs. These biomarkers will be evaluated for use as secondary and exploratory endpoints in 2A setting within this protocol.

Study Drug Rationale Given the increasing need for novel regimens and highly eqective, well-tolerated drugs to treat participants with TB, it is important to evaluate the antituberculosis activity of established anti- TB drugs that have been enhanced to generate higher eqicacy, lower adverse eqects, or both. These evaluations should occur in a carefully conducted, controlled, and standardised EBA study to determine their contributions as building blocks for potential future studies of new regimens. The results of this study will be used to support future studies of longer duration. Activity rationale: Extending the EBA duration from 7 to 14 days is informed by data suggesting that the full antimycobacterial eqect of alpibectir may not be completely observable within the 7-day period, thus a longer duration allows for a more accurate assessment of its activity and safety. The absence of human data at this dose level warrants careful monitoring, but the potential benefits of a more eqective treatment regimen for INH-resistant and other DR-TB justify this exploration. Safety rationale: The inclusion of a 45 mg dose of alpibectir in this study, despite not having been tested in previous phase 1 or 2 trials, is expected to be safe and well tolerated. Appropriate safety measures are in place to monitor participants throughout their treatment and evaluation of this premise. Pharmacodynamic scaling from pre-clinical models to humans suggests that the higher dose is likely to maximize therapeutic activity while maintaining a favourable safety profile. Given the promising preclinical and phase 2A results, it is both scientifically justified and ethically responsible to optimise the dose of alpibectir in a controlled clinical trial. The trial design includes comprehensive safety assessments to identify and manage any adverse events promptly. The investigation of 14 days in a 5-drug regimen (A45E250RZE) will provide crucial pilot safety and tolerability data. Hepatotoxic eqects associated with RZE-based regimens may occur later in treatment, and therefore 14-day data will provide some evidence on the safety of the regimen when moving into later phases of development. This approach ensures that any potential hepatotoxic eqects or other adverse events are identified and managed early, thereby safeguarding participants and informing future phase studies.

Control rationale: HRZE is being used as the control arm as the current SOC for PTB. Using HRZE allows for a direct comparison of the safety of the diqerent study arms against WHO approved regimen, and a microbiological control.

Rationale for the Selection of the Agents and Doses Alpibectir Alpibectir increases intra-bacterial bioactivation of Eto and as such works in combination with Eto to enhance Eto exposure in TB without increasing the dose of Eto. The selection of a 45 mg dose of alpibectir is based on pharmacodynamic scaling from animal models to humans, which indicates that this dose is likely to maximize therapeutic activity while maintaining a favourable safety profile, as evidenced by substantial bacterial load reduction in preclinical trials. Preclinical data showing that alpibectir at doses of up to 1.6 mg/kg prevented mortality in a BALB/c mouse model, suggesting a protective eqect of the drug at higher doses. Combination therapy arms with alpibectir and Eto are grounded in the compound's ability to enhance the bactericidal effect of Eto, as proven in pre-clinical trials and the recent phase 2 EBA. The trial seeks to further evaluate the potential of reducing the effective dose of Eto required, thus potentially reducing the drug's side effects, and enhancing patient tolerability.

Regimens explored in the TASK-010 trial evaluating doses of 9 mg and 27 mg of alpibectir along with Eto 120-500 mg, when pooled with the ENABLE 45 mg alpibectir and 125-250 mg Eto will support PKPD modelling and establish a robust dose-response curve to support the best dose combination.

Ethionamide Two doses of Eto will be used in this study, 125 mg, and 250 mg. EBA was seen in both doses when combined with alpibectir 27 mg in the recent TASK-010 phase 2a trial, these doses were also well tolerated in participants. The aim is to maintain a low, active dose of Eto in combination with alpibectir to ensure tolerability.

Rifampicin (A45E250RZE) The inclusion of a combination arm with alpibectir, Eto and RZE (Rifampicin, Pyrazinamide and Ethambutol) is designed to evaluate the EBA of the combination as part of a comprehensive TB treatment regimen. This could potentially inform the design of further trials. Additionally, we aim to assess whether the AlpE combination can serve as a viable alternative INH, particularly in situations where INH cannot be used due to resistance or other contraindications. This study will focus on the safety of the A45E250RZE combination.

Pyridoxine All participants will receive pyridoxine as prophylaxis against isoniazid-related or ethionamide related peripheral neuropathy, as per the National TB Guidelines. Currently this is 25 mg orally once daily, or with each dose of isoniazid or ethionamide.

ART Using the multi-cohort design, the early safety of the AlpE combination at higher alpibectir doses will be determined, as well as the safety of the A45E250RZE combination. In South Africa, between 1/3 and ½ patients diagnosed with TB are co-infected with HIV. It is important to understand the impact ART will have on the activity of any TB drug or regimen. As such, we have elected to include participants with HIV/TB co-infection who are receiving one of a limited number of ART options currently recommended as first line therapy. Inclusion of this critical group is unlikely to have significant impact either on the activity of the regimens, or on the efficacy of the ART as determined by the known effect of each drug on inhibiting or inducing various substrates involved in metabolism. This allows the study to generate early safety data with minimal risk to the participants. The ART regimens permitted include 2 non-nucleoside reverse transcriptase inhibitors (NRTI) and dolutegravir. The NRTI's permitted may include Emtricitabine, Lamivudine and/or Tenofovir.

Dolutegravir (Mondleki, 2022):

  • Dolutegravir does not induce or inhibit metabolising enzymes. Dolutegravir is a substrate of the drug efflux pumps P-gp and BCRP. It is primarily metabolised by enzyme UGT1A1, and to a smaller degree by CYP3A4, and UGT1A3 and 1A9.
  • Alpibectir has a minimal risk of inhibition of CYP3A4, P-gp, and BCRP (section 3.1). No information is available about the effect of alpibectir on UGT1A1, although in vitro work is planned and will be conducted. INH has a small effect on CYP3A4 inhibition, this effect may be more pronounced in slow acetylators though the clinical effect is likely modest.
  • Based on the currently available data in which lower concentrations of dolutegravir were found when co-administered with rifampicin but not impact on viral suppression was demonstrated, a clinically significant drug-drug interaction between dolutegravir and the AlpE combination or HRZE are not anticipated (Sekaggya-Wiltshire, 2023). Current South African Department of Health guidelines recommend increasing the dose of dolutegravir to 50 mg twice daily (from 50 mg daily)(Primary Care Guide, 2021). This will be implemented in participants randomized to arms receiving rifampicin.

Emtricitabine, Lamivudine, Tenofovir (NRTIs)

  • Emtricitabine, lamivudine and tenofovir are not substrates or inhibitors of CYP enzymes but are substrates for various transporter proteins. For example, Tenofovir is a substrate of BCRP/ABCG2 and P-glycoprotein/ABCB1, and an inhibitor of MRP2 (Wassner, 2020).
  • Based on the currently available data, a clinically significant drug-drug interaction between the NRTIs and the AlpE combination or RZE are not anticipated.
03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Alpibectir
  • Ethionamide
  • Rifampicin
  • Pyrazinamide
  • Ethambutol
  • Adults
  • Newly Diagnosed
  • Drug- Susceptible
  • Pulmonary Tuberculosis
04

In context

Tuberculosis, Pulmonary Reclassified

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

This study's planned enrollment of 60 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

TASK Applied Science is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written, prior to all trial-related procedures and willing to adhere to all required study procedures and restrictions for the duration of the trial.
  2. Male or female, aged between 18 and 65 years, inclusive.
  3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
  4. Newly diagnosed and untreated for this episode of pulmonary TB.
  5. Rifampicin- and isoniazid susceptible pulmonary TB as determined by molecular testing (GeneXpert XDR or Genotype MTBDRplus for INH).
  6. A chest X-ray taken during the screening period or up to 2 weeks before screening which, in the opinion of the investigator, is consistent with TB.
  7. GeneXpert positive with a quantitative readout of medium or high.
  8. Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).
  9. Be of non- or of childbearing potential using effective methods of , as defined in section 5.2 and in Appendix 1.

    Female Participants

  10. For WOCBP who are not already receiving contraception per Appendix 1 requirements, agree to receive injectable or other contraceptive methods (per Appendix 1), to be given during screening, and at least 1 day prior to first dose of IMP.

    Male Participants

  11. Agree to ALL of the following during the study intervention period and for at least 90 days, after the last dose of study intervention:

    1. Refrain from donating fresh unwashed semen
    2. Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator.
  2. Poor general condition where any delay in treatment cannot be tolerated per discretion of the investigator.
  3. History of epilepsy, seizures or other neuropsychiatric disorders that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator.
  4. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  5. History of hypothyroidism
  6. of >450 ms at baseline
  7. Clinically significant evidence of extra-thoracic TB, as judged by the investigator.
  8. History of allergy to any of the trial IMP as confirmed by the clinical judgement of the investigator.
  9. Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant.
  10. positive AND:

    1. CD4 \< 250cells/mm3
    2. On other ART regimen not listed below or, if not on ART they are not willing to wait to start treatment until completion of study regimen

    Note: ART regimens permitted is limited to the following in line with local guidelines for ART:

    • NRTIs selected from: Emtricitabine, Lamivudine, Tenofovir
    • PLUS Dolutegravir 50 mg daily, or 50 mg twice daily if randomized to a rifampicin containing arm.

    Participants established on ART (2 NRTIs and dolutegravir) for more than 30 days at start of screening are eligible for participation.

    As the drug-drug interaction potential of ART has not been fully investigated with the IMP, NNRTIs (efavirenz, nevirapine) and other protease inhibitors will not be permitted in this study.

  11. Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of study intervention. Male participant planning to conceive a child for at least 90 days, after the last dose of study intervention in the trial.

    Treatment History

  12. Participation in other clinical studies with agents within 8 weeks prior to screening.
  13. Treatment received for this episode of TB with any drug active against M. tb (including but not limited to isoniazid, ethambutol, cycloserine, fluoroquinolones, rifamycins, aminoglycosides, nitroimidazoles, bedaquiline, oxazolidinones, para-amino salicylic acid, pyrazinamide, thioacetazone, thioamides).
  14. Treatment with medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic for more than 7 days within 2 weeks prior to screening.
  15. Unavoidable treatment with prohibited concomitant medications (see section 5.3.2) anticipated during administration of IMP.

    Laboratory Safety Testing

  16. Presence of surface antigen (HBsAg+)
  17. Positive antibody test result (HCV IgG+)
  18. Participants with the following toxicities at screening as defined by the enhanced toxicity table:

    1. creatinine >1.5 times (ULN)
    2. \<8.0 g/dL
    3. \<50x109 cells/L
    4. serum potassium \<3.0 mmol/L
    5. (ALT) ≥5 x ULN
    6. total >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5 x ULN as long as direct bilirubin is ≤1.5xULN
    7. Total white cell count \<1.5 cells/L
    8. Thyroid Stimulating Hormone > ULN
    9. Glucose \< 3.5 mmol/L
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Arm 1 (A45E125)

    Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD

    Drug: Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD

  • Experimental
    Cohort 1 Arm 2 (A45E250)

    Alpibectir 45 mg OD plus Ethionamide 250 mg OD

    Drug: Alpibectir 45 mg OD plus Ethionamide 250 mg OD

  • Active comparator
    Cohort 1 Arm 3 (HRZE)

    Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

    Drug: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

  • Active comparator
    Cohort 2 Arm 3 (HRZE)

    Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

    Drug: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

  • Experimental
    Cohort 2 Arm 4 (A45E250RZE)

    Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD

    Drug: Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD

Interventions

  • DrugAlpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD

    Drug page: AlpibectirStudies of AlpibectirAlpibectir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cohort 1 Arm 1

  • DrugAlpibectir 45 mg OD plus Ethionamide 250 mg OD

    Drug page: AlpibectirStudies of AlpibectirAlpibectir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cohort 1 Arm 2

  • DrugIsoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

    Active Comparator

  • DrugAlpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD

    Drug page: AlpibectirStudies of AlpibectirAlpibectir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cohort 2 Arm 4

07

What researchers measure

Primary outcomes

  1. EBA-TTP (0-14)

    The EBA TTP (0-14) as determined by the rate of change in log10TTP in sputum over the period day 0 (baseline sample) to Day 14 will be described using linear, bi-linear, or non-linear functions using nonlinear mixed effects modelling of log10TTP over time. Estimates of rates of change including uncertainties for each treatment group will be given and graphically illustrated.

    Time frame: 14 days

Secondary outcomes

  1. EBA CFU (0-14)

    The EBA CFU (0-14) as determined by the rate of change in log10CFU per ml sputum over the period day 0 to day 14 will be described using linear, bi-linear, or non-linear functions using nonlinear mixed effects modelling as dictated by the data of log10CFU over time. Estimates of rates of change including uncertainties for each treatment group will be given and graphically illustrated.

    Time frame: 14 days

  2. EBA (0-2) and EBA (2-14)

    The EBA (0-2) and EBA (2-14) determined by the rate of change in The EBA (0-2) and EBA (2-14) determined by the rate of change in log10CFU and log10TTP over time.

    Time frame: 2-14 days

  3. Safety and tolerability

    The incidence of the following events will be summarized by treatment group: * Incidence of treatment-emergent adverse events (TEAEs). * Incidence of TEAEs by Severity. * Incidence of drug related TEAEs. * Incidence of Serious TEAEs. * Incidence of TEAEs leading to treatment discontinuation. * Incidence of TEAEs leading to early withdrawal from the study. * Incidence of TEAEs leading to death. Descriptive summary statistics will be presented for other safety variables: laboratory parameters, physical examination, vital signs, concomitant medication

    Time frame: 14 days

  4. PK analysis - Cmax

    Maximum observed plasma drug concentration (Cmax),

    Time frame: 14 days

  5. Biomarkers (Sputum)

    The EBA MBLA (0-14) and EBA LAM (0- 14) as determined by the rate of change in biomarker over the period day 0 to day 14 will be described using linear, bi-linear, or non-linear functions using nonlinear mixed effects modelling as dictated by the data of biomarker over time. Estimate of rates of change including uncertainties for each treatment groups will be given and graphically illustrated. treatment arm, based on the mycobacterial load assay (MBLA) and PATHFAST TB Lipoarabinomannan (LAM) test.

    Time frame: 14 days

  6. Biomarkers (Whole Blood)

    Descriptive statistics will be computed for each biomarker.

    Time frame: 14 days

  7. Mycobacterial parameters

    Cultures from baseline (Day -2, Day - 1) and post-baseline (Day 14) will be kept. In case end of treatment cultures are not available the last available culture after day 8 will be kept. Determination of the minimum inhibitory concentration (MIC) of the investigational agents will be done. If a significant MIC shift (≥4-fold) of these drugs is observed, MIC determination of all regimen agents will be triggered and genome sequencing of isolates with the shift in MIC will be performed.

    Time frame: 2-14 days

  8. Drug-drug interaction - AUC (0-24)

    The AUC (0-24) of alpibectir with and without rifampicin will be compared.

    Time frame: 14 days

  9. PK Analysis (AUC (0-24), AUC (0-∞), AUC(0-tau)

    Area under the plasma drug concentration versus time curve ((AUC (0-24), AUC (0-∞), AUC(0-tau))

    Time frame: 14 days

  10. PK Analysis (Tmax)

    Time to maximum observed plasma drug concentration (Tmax),

    Time frame: 14 days

  11. PK Analysis - apparent terminal half-life (t1/2)

    Apparent terminal half-life (t1/2), as appropriate will be estimated for alpibectir, Eto and Eto-SO using a noncompartmental approach.

    Time frame: 14 days

  12. PK Analysis-Descriptive Statistics

    Mean, standard deviation, coefficient of variation, median, minimum, and maximum, geometric mean, and geometric mean coefficient of variation (CV)% will be computed for each PK parameter.

    Time frame: 14 days

  13. Drug-drug interaction - Cmax

    The Cmax of alpibectir with and without rifampicin will be compared.

    Time frame: 14 days

  14. Drug-drug interaction - Tmax

    The Tmax of alpibectir with and without rifampicin will be compared. \[

    Time frame: 14 days

08

Study locations

1 of 1 sites recruiting
  • TASK
    Cape Town, Western Cape 7550, South Africa
    Recruiting
    • Gifty Okyere-Manu, MBChB · Contactdrgifty@task.org.za · +27 21 831 6564
    • Vani Govender, Honors Medical Biochemistry · Contactvani.g@task.org.za · +27 21 831 6564
    • Gifty Manu-Okyere, MBChB · Principal investigator
    • Fairoez Ryklief, MBChB · Sub investigator
    • Trishnabye Mahadea, MBChB · Sub investigator
09

References and documents

Related links

Individual participant data

Plan to share: No — Data will be shared based on the following principles: No data should be released that would compromise an ongoing trial or study. There must be a strong scientific or other legitimate rationale for the data to be used for the requested purpose. Investigators who have invested time and effort into developing a trial or study should have a period of exclusivity in which to pursue their aims with the data, before key trial data are made available to other researchers. The resources required to process requests should not be under-estimated, particularly successful requests which lead to preparing data for release. Therefore adequate resources must be available in order to comply in a timely manner or at all, and the scientific aims of the study must justify the use of such resources. Data exchange complies with Information Governance and Data Security Policies in all of the relevant countries.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

Of 33 non-industry phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 12 months is below that.

Counting every sponsor, half of 43 studies reached it within 30 months; a quarter within 21 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 27, 2024
StartActual
Mar 3, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Mar 30, 2026
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06748937
Lead sponsor
TASK Applied Science
Collaborators
Innovative Medicines Initiative
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Mar 3, 2025
Primary completion
Mar 30, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Mar 7, 2025

Study contacts

Gifty Okyere-Manu, MBChB
Contact
dr.gifty@task.org.za
0211002046
Vani Govender, Masters Medical Science
Contact
vani.g@task.org.za
0211002046
Gifty Okyere-Manu, MBChB
principal investigator · TASK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpibectir

Start the discussion